MUC16 and ovarian carcinoma: Subsequently, publication of the results of the ovarian arm of the randomized, controlled Prostate Lung Colorectal Ovarian (PLCO) study comparing serum CA125 testing plus transvaginal ultrasound with no screening in over 78,000 women aged 55 to 74 years did not show an ovarian cancer specific survival benefit associated with ovarian cancer screening [4], even with extended follow-up of a median of 15 years [5].